Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Jeffrey Yorio

Hematology Oncology
Texas Oncology
Texas Oncology PA
2410 Round Rock Ave, Suite 150, 
Round Rock, TX 
Offers Telehealth

Experienced in WT1-Related Wilms Tumor Syndromes
Texas Oncology
Texas Oncology PA
2410 Round Rock Ave, Suite 150, 
Round Rock, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jeffrey Yorio is a Hematologist Oncology provider in Round Rock, Texas. Dr. Yorio is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Myelodysplastic Syndrome (MDS), and Paroxysmal Nocturnal Hemoglobinuria (PNH).

His clinical research consists of co-authoring 12 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in TX
Hospital Affiliations
Ascension Seton Medical Center Austin
North Austin Medical Center
St David's Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
FirstCare
  • HMO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Moda Health
  • EPO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sendero
  • HMO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
US Health and Life
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 21 Less Insurance Carriers -

Locations

TEXAS ONCOLOGY PA
2410 Round Rock Ave, Suite 150, Round Rock, TX 78681
Call: 512-341-8724

Additional Areas of Focus

Dr. Yorio has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


4 Clinical Trials

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered With First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients With Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)
A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered With First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients With Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)
Enrollment Status: Terminated
Publish Date: September 08, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Cisplatin, Carboplatin, Avelumab
Study Phase: Phase 2
A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies
A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drugs: Brentuximab vedotin, Pembrolizumab
Study Phase: Phase 2
A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
Enrollment Status: Terminated
Publish Date: August 23, 2024
Intervention Type: Drug
Study Drugs: Selinexor, Pembrolizumab
Study Phase: Phase 2
View 3 Less Clinical Trials

12 Total Publications

Estimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients.
Estimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients.
Journal: BMC health services research
Published: April 23, 2024
View All 12 Publications
Similar Doctors
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Meaghan L. Dubin
Hematology Oncology | Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Meaghan L. Dubin
Hematology Oncology | Hematology | Oncology

Scott And White Clinic

2401 S 31st St, 
Temple, TX 
 (44.4 miles away)
254-724-2459
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Meaghan Dubin is a Hematologist Oncology specialist and a Hematologist in Temple, Texas. Dr. Dubin is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Childhood Iron Deficiency Anemia, Schnitzler Syndrome, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Iron Deficiency Anemia. Dr. Dubin is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Mohammed H. Sabbagh
Oncology | Hematology | Hematology Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Mohammed H. Sabbagh
Oncology | Hematology | Hematology Oncology

American Oncology Partners PA

3201 S Austin Ave, Suite 315, 
Georgetown, TX 
 (7.4 miles away)
512-358-9428
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mohammed Sabbagh is an Oncologist and a Hematologist in Georgetown, Texas. Dr. Sabbagh is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Myelodysplastic Syndrome (MDS), Familial Wilms Tumor 2, WT1-Related Wilms Tumor Syndromes, and Wilms Tumor. Dr. Sabbagh is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Beth A. Hellerstedt
Hematology Oncology | Oncology | Hematology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Beth A. Hellerstedt
Hematology Oncology | Oncology | Hematology

Texas Oncology PA

2410 Round Rock Ave, Suite 150, 
Round Rock, TX 
 (0.1 miles away)
512-341-8724
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Beth Hellerstedt is a Hematologist Oncology specialist and an Oncologist in Round Rock, Texas. Dr. Hellerstedt is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Urothelial Cancer, and Familial Colorectal Cancer. Dr. Hellerstedt is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Yorio's expertise for a condition
ConditionClose
    • Distinguished
    • Lung Cancer
      Dr. Yorio is
      Distinguished
      . Learn about Lung Cancer.
      See more Lung Cancer experts
    • Myelodysplastic Syndrome (MDS)
      Dr. Yorio is
      Distinguished
      . Learn about Myelodysplastic Syndrome (MDS).
      See more Myelodysplastic Syndrome (MDS) experts
    • Pleuropulmonary Blastoma
      Dr. Yorio is
      Distinguished
      . Learn about Pleuropulmonary Blastoma.
      See more Pleuropulmonary Blastoma experts
    • Advanced
    • Acute Mountain Sickness
      Dr. Yorio is
      Advanced
      . Learn about Acute Mountain Sickness.
      See more Acute Mountain Sickness experts
    • Cholangiocarcinoma (Bile Duct Cancer)
      Dr. Yorio is
      Advanced
      . Learn about Cholangiocarcinoma (Bile Duct Cancer).
      See more Cholangiocarcinoma (Bile Duct Cancer) experts
    • Iron Deficiency Anemia
      Dr. Yorio is
      Advanced
      . Learn about Iron Deficiency Anemia.
      See more Iron Deficiency Anemia experts
    • Melanoma
      Dr. Yorio is
      Advanced
      . Learn about Melanoma.
      See more Melanoma experts
    • Paroxysmal Nocturnal Hemoglobinuria (PNH)
      Dr. Yorio is
      Advanced
      . Learn about Paroxysmal Nocturnal Hemoglobinuria (PNH).
      See more Paroxysmal Nocturnal Hemoglobinuria (PNH) experts
    • Pulmonary Embolism
      Dr. Yorio is
      Advanced
      . Learn about Pulmonary Embolism.
      See more Pulmonary Embolism experts
    View All 7 Advanced Conditions
    • Experienced
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Yorio is
      Experienced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Yorio is
      Experienced
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    • Acute Myeloid Leukemia (AML)
      Dr. Yorio is
      Experienced
      . Learn about Acute Myeloid Leukemia (AML).
      See more Acute Myeloid Leukemia (AML) experts
    • Adult Soft Tissue Sarcoma
      Dr. Yorio is
      Experienced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Agranulocytosis
      Dr. Yorio is
      Experienced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Yorio is
      Experienced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    View All 108 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2025 All Rights Reserved